Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

A new lung adenocarcinoma classification has been published by the International
Association for the Study of Lung Cancer, the American Thoracic Society, and the European …

Purpose: A significant proportion of mucosal melanomas contain alterations in KIT. The aim
of this study was to characterize the pattern of KIT, NRAS, and BRAF mutations in mucosal …

Background: EGFR and KRAS mutations are mutually exclusive and predict outcomes with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …

Background Anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer
(NSCLC) is markedly sensitive to the ALK inhibitor crizotinib. However, acquired resistance …

K-RAS gene mutations have been found in 20–30% of non-small cell lung cancer and occur
most commonly in adenocarcinoma, however, there was no definitive conclusion about the …

Background Epithelial growth factor receptor (EGFR) and KRAS mutation status have been
reported as predictive markers of tumour response to EGFR inhibitors. High resolution …

Introduction Therapies targeting programmed cell death-1 (PD-1) and its ligand (PD-L1)
have been successful in a subset of patients with non–small-cell lung cancer (NSCLC). PD …

Introduction This study compared the efficacy of pemetrexed in patients with anaplastic
lymphoma kinase (ALK)-positive versus ALK-negative (epidermal growth factor receptor …

Compound EGFR mutations, defined as double or multiple mutations in the EGFR tyrosine
kinase domain, are frequently detected with advances in sequencing technology but its …